Two Cheers for Conventional Wisdom
The real source of first-mover advantage, much extolled in the dot com world and among the advocates of unfettered innovation, is as often luck as it is vision. The problem is that, when these major strategic moves fail--and most of them do--there's no inexpensive way to retreat.
You may also be interested in...
Despite the millions of dollars from public initiatives, particularly in California, to fund stem-cell research, VCs will still probably stay away until Big Pharma and Big Biotech show more of their own R&D interest in the area.
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.